Diego Carbonell
Overview
Explore the profile of Diego Carbonell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de la Iglesia-San Sebastian I, Lopez-Esteban M, Bastos-Oreiro M, Fernandez de Cordoba-Onate S, Gutierrez M, Carbonell D, et al.
Br J Haematol
. 2024 Dec;
206(1):195-203.
PMID: 39668521
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for aggressive B-cell lymphomas (ABCL), However, about half of patients relapse, most of them early. This study investigates...
2.
de la Iglesia-San Sebastian I, Carbonell D, Bastos-Oreiro M, Perez-Corral A, Bailen R, Chicano M, et al.
Transplant Cell Ther
. 2024 Jan;
30(3):306.e1-306.e12.
PMID: 38184148
Chimeric antigen receptor T cells (CAR-T) has emerged as a promising therapy, over 60% of patients fail to sustain a long-term response. The underlying factors that leads to the effectiveness...
3.
Carbonell D, Monsalvo S, Catala E, Perez-Corral A, Villegas C, Falero C, et al.
Blood Transfus
. 2023 Dec;
22(3):239-245.
PMID: 38063787
Background: Chimeric antigen receptor (CAR) T-cell therapy is increasingly used in patients affected by B-cell lymphoma and acute lymphoblastic leukemia. For logistical reasons, initial apheresis products may be cryopreserved for...
4.
Gil-Manso S, Herrero-Quevedo D, Carbonell D, Martinez-Bonet M, Bernaldo-de-Quiros E, Kennedy-Batalla R, et al.
PLoS Pathog
. 2023 Jun;
19(6):e1011432.
PMID: 37311004
Background: SARS-CoV-2 emerged as a new coronavirus causing COVID-19, and it has been responsible for more than 760 million cases and 6.8 million deaths worldwide until March 2023. Although infected...
5.
Gomez-Centurion I, Rojas R, Bailen R, Munoz C, Sabell S, Oarbeascoa G, et al.
Ann Hematol
. 2023 Apr;
102(6):1561-1567.
PMID: 37083956
This is a retrospective cohort study of consecutive adult patients who received a haploidentical-SCT (haplo-SCT) with post-transplant cyclophosphamide (PT-Cy) in a single centre. Poor graft function (PGF) was defined as...
6.
Bastos-Oreiro M, Sanz-Villanueva L, Muniz P, Bailen R, Chicano M, Oarbeskoa G, et al.
Transplant Cell Ther
. 2023 Mar;
29(7):472.e1-472.e4.
PMID: 36921917
We propose a novel biomarker that can identify patients at high risk of early progression after chimeric antigen receptor (CAR) T cell therapy. Calculation of cell-free DNA (cfDNA) with a...
7.
Muniz P, Andres-Zayas C, Carbonell D, Chicano M, Bailen R, Oarbeascoa G, et al.
Front Immunol
. 2022 Oct;
13:1002959.
PMID: 36211438
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for patients with hematologic malignances. Haploidentical HSCT (Haplo-HSCT) is an alternative option for patients who do not have an HLA-matched...
8.
Carbonell D, Chicano M, Cardero A, Gomez-Centurion I, Bailen R, Oarbeascoa G, et al.
Cancers (Basel)
. 2022 Aug;
14(16).
PMID: 36010999
-internal tandem duplication (ITD) analysis is not typically performed in cDNA samples and is not considered an appropriate marker for monitoring measurable residual disease (MRD). The aims of this study...
9.
de Tena P, Bailen R, Oarbeascoa G, Gomez-Centurion I, Perez-Corral A, Carbonell D, et al.
Transfusion
. 2022 Aug;
62(10):2143-2147.
PMID: 35986653
Background: A variable incidence of profound cytopenia has been described in patients receiving chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL). This...
10.
Gil-Manso S, Carbonell D, Perez-Fernandez V, Lopez-Esteban R, Alonso R, Munoz P, et al.
Biomedicines
. 2022 Jul;
10(7).
PMID: 35884980
Vaccination against SARS-CoV-2 has become the main method of reducing mortality and severity of COVID-19. This work aims to study the evolution of the cellular and humoral responses conferred by...